Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline - Summary - MDSpire

Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline

New innovations targeting dry eye disease (DED) are in the pipeline to enable us to tailor our treatments to the specific underlying causes of DED.

  • By

  • SHANE R. KANNARR, OD

  • Christoper J. Jacquinot, OD

  • Ryan A. Cedeno, OD

  • July 1, 2025

  • 1 min

Share

Objective:

To discuss new treatment options in development for dry eye disease (DED).

Approach:
    Key Findings:
    • Reproxalap may reduce inflammation in DED and allergy patients.
    • AZR-MD-001 could enhance meibum quality in meibomian gland dysfunction.
    • OCS-02 targets ocular inflammation related to DED.
    • Softacort may alleviate symptoms when used with proper lid care.
    Interpretation:

    These emerging therapies represent a tailored approach to treating the underlying causes of dry eye disease.

    Conclusion:

    The development of these pharmaceuticals indicates progress in addressing the diverse mechanisms of dry eye disease.

Original Source(s)

Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline

  • by SHANE R. KANNARR, OD, Christoper J. Jacquinot, OD, Ryan A. Cedeno, OD

  • July 1, 2025

Related Content

Women and Dry Eye

Presenters at Optometry's Meeting noted that hormonal status and cosmetic use can significantly affect test results and dry eye disease presentation.

Dry Eye Dx and Tx: <br>Tailoring the Tear Reservoir</br>

Scleral Lens Evolution

This article will examine the indications, clinical evidence, and practical considerations for managing severe ocular surface disease and inflammatory dry eye using scleral lenses, and offer guidance to practitioners who seek to expand their therapeutic options.